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                                                     ABSTRACT 
INTRDUCTION: 
        Magnesium is the second most important intracellular cation in the 
body next only to potassium. It acts as a cofactor in more than 300 enzymatic 
reactions involving energy metabolism and nucleic acid synthesis. Magnesium 
deficiency inhibits the acute phase of insulin release in response to glucose 
challenge. Magnesium deficiency is associated with insulin resistance; conversely 
insulin resistance is associated with low serum magnesium. Hypomagnesemia in 
patients with diabetes results from poor oral intake, poor gastrointestinal 
absorption and enhanced renal magnesium excretion. Microalbuminuria and overt 
proteinuria in patients with diabetes contribute to renal magnesium wasting due to 
protein bound magnesium loss. There exists an inverse correlation between serum 
magnesium level and diabetic patients with proteinuria. More the proteinuria , 
more the magnesium loss, lesser the serum magnesium level. 
AIMS AND OBJECTIVES: 
           To study the correlation of serum magnesium in diabetic patients with 
proteinuria. 
 
MATERIALS AND METHODS: 
           This was an observational study done in Government Royapettah 
Hospital.The study recruited 50 patients ,who were admitted in the department of 
medicine and who attended diabetology department as out patients.Those who 
fulfilled the  inclusion and exclusion criteria were included in the study.Serum 
Magnesium level  and 24hours urinary protein were estimated. 
Observation and results: 
         Out of 50 patients recruited in the study 12 patients were type 1 and 38 were 
type 2.Out of 50 patients 25 patients had microalbuminuria and 25 patients had 
macroalbuminuria.Those patients who had macroalbuminuria had lower  
magnesium level compared to patients who had microalbuminuria.Patients who 
had more proteinuria had the lowest magnesium level. 
CONCLUSION: 
      The study concluded that there is an inverse correlation between serum 
magnesium level and proteinuria.As deficiencyof magnesium is involved in many 
complications of diabetes ,supplementing oral magnesium can reduce morbidity 
and mortality. 
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           INTRODUCTION 
 
Magnesium is an important element in the body. It is the fourth 
most common cation in the body and the second most common 
intracellular cation after potassium
1
. It acts as a cofactor in more than 300 
enzymatic reactions involving energy metabolism and nucleic acid 
synthesis
2
. Less than 1% of total body Magnesium is found in serum and 
red blood cells
3
. Deficiency of magnesium has been implicated in a 
number of disorders. 
Magnesium is involved in glucose homeostasis. Deficiency of 
magnesium gives rise to alterations in glucose metabolism. Magnesium 
affects insulin secretion as well as glucose uptake by cells. Magnesium 
deficiency inhibits the acute phase of insulin release in response to 
glucose challenge. Magnesium deficiency is associated with insulin 
resistance; conversely insulin resistance is associated with low serum 
magnesium
4
. 
Hypomagnesemia in patients with diabetes results from poor oral 
intake, poor gastrointestinal absorption and enhanced renal magnesium  
excretion
5
. In diabetes, ultra filterable magnesium load may be enhanced 
by  glomerular hyper filtration, recurrent excessive volume depletion  due 
to hyperglycemia induced osmotic diuresis, recurrent metabolic acidosis 
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associated with diabetic ketoacidosis and hypoalbuminemia. 
Microalbuminuria and overt proteinuria in patients with diabetes 
contribute to renal magnesium wasting due to protein bound magnesium 
loss. 
There is an inverse correlation between serum magnesium and 
serum cholesterol, triglyceride, low density lipoprotein level
6
. In patients 
with hypomagnesemia these lipids are at a higher level. Magnesium 
deficiency increases angiotensin II induced plasma aldosterone 
concentration and production of thromboxane and vasoconstrictor 
prostaglandin. These changes lead to increase in vascular tone. 
Magnesium deficiency leads to progression of atherosclerosis by its effect 
on lipid metabolism, platelet aggregation and blood pressure
7
. Thus it can 
lead to increase in cardiovascular related mortality. 
There exists an inverse correlation between serum magnesium level 
and diabetic patients with proteinuria. More the proteinuria , more the 
magnesium loss, lesser the serum magnesium level
8
. 
Thus by treating these patients with oral magnesium, we can 
improve glycemic control and can prevent other vascular complication 
related to diabetes
9
. 
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REVIEW OF LITERATURE 
DEMOGRAPHY: 
India is having the world’s largest number of diabetic patients. 
Type 2 diabetes accounts for more than 90% of cases and Type 1 diabetes 
is on the increasing trend. International Diabetes Federation (IDF) said 
that total number of diabetics in India was around 40.9million in the year 
2006, and it projected that it will become 69.9million by the year 
2025
10
.Study done in1998 in Chennai population showed a prevalence of 
8.2% in urban and 2.4%in rural areas
11
.A study done after 5 years in the 
same urban area showed a prevalence of 11.6%
12
. 
Chennai Urban Rural Epidemiology study (CURES), showed that 
the prevalence of diabetes in Chennai was 15.5% and that of impaired 
glucose tolerance was10.6%.The prevalence of diabetes in Chennai 
increased by 39.8% from 1989 to1995.It increased by 16.5% from the 
year 1995 to 2000 and by 6% between 2000 to 2004.Thus the prevalence 
of diabetes increased significantly by 72.3% within the span of 14years
13
.  
Diabetic nephropathy develops in one third of the patients with 
diabetes. The incidence is increasing worldwide and the Asia pacific 
region being the most affected. According to statistical prediction, in 
India diabetic nephropathy is expected to develop in 6.6million people 
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out of 30million people with  diabetes
14
. Studies in south India have 
shown that the prevalence of microalbuminuria is 26.9% and overt 
proteinuria is 2.2%
15
.Prevalence of diabetic nephropathy in Asia in 
Vellore (India) was 8.9%, and Asians in Leicester, United Kingdom was 
22.3% and Caucasians in Leicester, in United Kingdom was 12.6%
16
. 
25to 39% of patients with diabetes will have low serum magnesium level. 
Diabetes mellitus is a group of common metabolic disorders that 
share the phenotype of hyperglycemia. Several types of diabetes mellitus 
are caused by complex interaction of environmental and genetic factors. 
Based on the etiology of the DM, factors contributing to increased blood 
sugar are decreased insulin secretion, reduced glucose utilization, and 
increased production of glucose. One of the most important causes of end 
stage renal disease in United States is diabetes mellitus. Because of the 
increasing incidence of diabetes mellitus it will be the most common 
cause of morbidity and mortality in the future 
17
.  
CLASSIFICATION OF DIABETES 
Diabetes has been broadly classified into two types: 
TYPE 1: It is due to near total or complete lack of insulin. 
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TYPE 2: It is due to insulin resistance, reduced insulin secretion 
and increased production of glucose. Impaired fasting glucose or 
impaired glucose tolerance precedes the development of diabetes. 
Criteria for the diagnosis of Diabetes
17
: 
1. Random blood glucose > 200mg/dl, plus symptoms of 
diabetes or 
2. Fasting plasma glucose > 126mg/dl or 
3. Hb A1C > 6.5% or 
4. Two hour plasma glucose during an oral glucose tolerance 
test more  than 200mg/dl            
Pathogenesis of Type 1 diabetes: 
Type 1 diabetes mellitus is the result of interaction of 
environmental, genetic and immunological factors that ultimately causes 
pancreatic β cell destruction and insulin deficiency. The rate of decline in 
β cells varies with individual, some patients’ progress slowly and others 
rapidly to clinical diabetes. Features of diabetes occur only when 70-80% 
of β cells are destroyed. At this stage residual β cell function exists, but 
are not sufficient to maintain glucose tolerance. Once the requirement of 
insulin increases as with any infection or puberty, they manifest as frank 
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diabetes. After the initial clinical presentation of type 1 DM, a 
"honeymoon" phase may ensue during which time glycemic control is 
achieved with modest doses of insulin or, rarely, insulin is not needed. 
However, this fleeting phase of endogenous insulin production from 
residual beta cells disappears as the autoimmune process destroys 
remaining beta cells, and the individual becomes insulin deficient
17
. 
GENETIC CONSIDERATION: 
Susceptibility to Type 1 DM involves multiple genes. Concordance 
in identical twin ranges between 40-60%.The susceptibility gene is 
located in the HLA region in chromosome 6.Most individual have HLA 
DR3 and or HLA DR4 haplotypes. The haplotypes DQA1
*
0301, 
DQB1
*
0302, and DQB1
*
0201 are strongly associated with type 1 DM
18
. 
However, most individuals with these haplotypes do not develop 
diabetes. The presence of haplotype DQA1
*
0102, DQB1
*
0602 gives 
protection against the development of Type 1 DM. 
PATHOPHYSIOLOGY: 
There is infiltration of pancreatic islet cells with lymphocytes 
(termed insulitis).After the destruction of β cells the inflammatory 
process stops and the islet cells become atrophic and the immunological 
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markers will disappear. The following abnormalities of cellular humoral 
immune response was found in patients with Type 1 DM 
      1. Islet cell auto antibodies 
      2. Proliferation of  T Lymphocyte when stimulated with islet proteins 
      3. Release of cytokines within the insulitis 
      4. Activated lymphocytes in the islets and systemic circulation.  
Insulin, glutamic acid decarboxylase, and a beta cell specific zinc 
transporter are the pancreatic islet cell molecule targeted by autoimmune 
process. 
Metabolic disturbances of Type 1 diabetes 
Carbohydrate metabolism: 
Basal hyperglycemia is due to increased production of glucose by 
the liver and is increased after eating because glucose is not cleared in the 
periphery. Hepatic glucose output is increased because of increased 
gluconeogenesis and supply of gluconeogenic precursor is increased. 
Postprandial glucose uptake into fat and muscle mediated by insulin is 
decreased. 
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Fat metabolism: 
Severe insulin deficiency stimulates lipolysis thereby generating 
glycerol and free fattyacids,which are substrates for ketone formation. 
Ketogenesis is particularly increased by glucagon excess. Weight loss in 
untreated type 1 diabetics is due to mobilization of body fat. 
Protein metabolism: 
Anabolic effect of insulin is lost, catabolism of proteins are 
increased through proteosome mediated  pathway and generates 
aminoacids such as alanine and glutamine which are precursors of 
gluconeogenesis. Muscle wasting may be  prominent
17
. 
TYPE 2 DIABETES: 
Central to the development of type 2 diabetes are insulin resistance 
and abnormal insulin secretion. The primary defect in diabetes mellitus is 
controversial, most studies support insulin resistance precedes the 
development of insulin secretory defect but diabetes occurs only when 
insulin secretions are not adequate. 
Genetic consideration: 
Type 2 diabetes mellitus has a strong genetic basis. The 
concordance of Type 2DM is between 70% and 90% in identical twins. 
 17 
Sibling of parent with type 2DM has an increased risk of getting diabetes. 
The risk approaches 40% if both parents are type 2 diabetic. The disease 
is multifactorial and polygenic in addition to genetic susceptibility; 
environment factors such as nutrition, obesity and physical activity also 
have a role. A variant of transcription factor 7 like 2 genes is associated 
with type 2 diabetes
17
. 
Pathophysiology: 
Type 2 diabetes is characterized by insulin resistance, reduced 
insulin secretion, abnormal fat metabolism and increased glucose 
production from the liver
19
.Visceral or central obesity is more common in 
type 2 diabetics. In the early stage of disease glucose tolerance remains 
near normal inspite of insulin resistance, because the pancreatic beta cells 
compensate by augmenting insulin output. Impaired glucose tolerance 
which is characterized by increase in postprandial blood sugar develops 
because of sustained hyperinsulinemic state due to insulin resistance and 
compensatory hyperinsulinemia. Once the insulin secretion declines 
further overt diabetes ensues with fasting hyperglycemia due to increased 
hepatic glucose production. 
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Metabolic abnormalities: 
Muscle and fat metabolism: 
 The prominent feature in type 2 DM is insulin resistance, which is 
mainly contributed by genetic susceptibility and obesity. Because of 
insulin resistance the activity of insulin in target tissues such as muscle, 
liver and fat is reduced. Insulin resistance in type 2 DM is relative, since 
there is circulating supra normal levels of insulin will normalize the blood 
sugar. Insulin resistance has two consequences  
1. It reduces the utilization of glucose by insulin sensitive tissues and  
2. It increases the output of glucose from the liver. These effects 
contributes to increase in plasma sugar level .Increased fasting 
plasma sugar is mainly due to increased hepatic glucose production 
and postprandial hyperglycemia is due to increased insulin 
resistance. In type 2 DM glucose metabolism in insulin 
independent tissue is unaffected. 
       The exact mechanism of insulin resistance is not known, but there is 
evidence to say that insulin at the receptor level and tyrosine kinase 
activity level are reduced in skeletal muscle. These changes are mainly 
secondary to hyperinsulinemia and not a primary defect. The important 
role in insulin resistance is played by the postreceptor defect in insulin 
 19 
regulated phosphorylation/ dephosphorylation
19
.Lipids gets accumulated 
within skeletal muscles and impairs mitochondrial oxidative 
phosphorylation, which in turn reduces insulin stimulated mitochondrial 
ATP production. Reactive oxygen species such as lipid peroxides gets 
accumulated within the skeletal muscles due to lipid accumulation and 
impaired fatty acid oxidation. 
Impaired insulin secretion: 
        Insulin secretion increases initially in response to hyperglycemia to 
maintain normal glucose tolerance. Insulin secretary defect is mild 
initially and only glucose stimulated insulin secretion is affected. There is 
abnormalities of  proinsulin  processing which is seen as increased in 
proinsulin level.The exact reason for insulin secretary defect is not 
known.The probable reason will be, there is a genetic defect 
superimposed upon insulin resistance and leads to β cell failure. In long 
standing cases of type 2 DM β cells secrete amyloid polypeptide or 
amylin which forms the amyloid fibrillar deposits in the islet cells
20
. 
Hepatic glucose and lipid production 
Increased Insulin resistance in liver cells results in fasting 
hyperglycemia because of failure of suppression of gluconeogenesis by 
hyperinsulinemia. Because of insulin resistance in adipose tissue flux of 
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free fatty acids and lipolysis from adipocytes are increased, leads to 
increased hepatic synthesis of lipids. This lipid steatosis in the liver leads 
to non alcoholic fatty liver disease. The dyslipidemia found in type2 DM 
are elevated triglyceride, reduced high density lipoprotein, and increased 
small dense low density lipoprotein particles
17
. 
Insulin resistance syndrome: 
The syndrome X or the insulin resistance syndrome is 
characterized by dyslipidemia, hypertension, visceral or central obesity, 
insulin resistance, type 2 diabetes or impaired fasting glucose or impaired 
glucose tolerance and accelerated cardiovascular disease. There are two 
types of severe insulin resistance in adults, 1.type A which occurs in 
young women and the features are obesity, severe hyperinsulinemia and 
hyperandrogenism.It is due to an undefined defect in insulin signaling 
pathway. 2. type 2 which occurs in middle aged women and the features 
are severe hyperinsulinemia, hyperandrogenism and autoimmune 
disorder.These individuals have autoantibodies directed against insulin 
receptor
21
. 
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COMPLICATIONS OF DIABETES: 
Acute metabolic complications are  
1. Diabetic ketoacidodis 
2. Hyperglycemic hyperosmolar state 
3. Hypoglycemia.  
DIABETIC KETOACIDOSIS: 
Diabetic ketoacidosis is more common in type 1 diabetes. 
Sometimes it may be the presenting feature in type 1 diabetes. It is less 
common in type 2 diabetes, but it can occur in type 2 diabetes. It is 
associated with relative or absolute insulin deficiency, volume depletion 
and acid base abnormalities. Counter regulatory hormones such as 
glucagon, cortisol, growth hormone and catecholamine play an important 
role in diabetic ketoacidosis
22
.Glucgon excess and insulin deficiency is 
necessary for diabetic ketoacidosis to develop. Decrease in insulin level 
augments the activity of phosphoenol pyruvate carboxykinase, increase in 
glucagon level reduces the activity of pyruvate kinase. These changes 
cause pyruvate to get converted to glucose. Increases in catecholamine 
level causes glycogenolysis. Increased levels of counter regulatory 
hormones and decreased levels of insulin causes increase in lipolysis and 
release of free fatty acids.The increased free fatty acids causes increase in 
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triglyceride and very lowdensity lipoprotein level.In diabetic keto 
acidosis, increase in glucagon level alters liver metabolism infavour of 
ketone body formation by activating the enzyme carnitine palmitoyl 
transferase 1. At normal pH these ketone bodies exist as ketoacids and 
these are neutralized by bicarbonate.Once bicarbonate stores are depleted 
metabolic acidosis ensures. 
CLINICAL FEATURES: 
Patients usually presents with thirst, polyuria, abdominal pain, 
nausea, vomiting and breathlessness. Diabetic ketoacidosis is precipitated 
by infarction, infection, inadequate dose of insulin administration .Drugs 
such as cocaine can precipitate. Pregnancy itself can precipitate diabetic 
ketoacidosis. Physical signs include dehydration, hypotension, tachypnea, 
tachycardia, respiratory distress, kussmals breathing.In case of severe 
acidosis lethargy, cerebral edema and coma can occur. 
LAB ABNORMALITIES AND DIAGNOSIS: 
Blood glucose is only mildly elevated. Serum bicarbonate is <10 
mmol/lit, the pH is in the range of 6.8 to 7.3 depending on the severity of  
acidosis. Hyperproteinemia, hypertriglyceridemia and leucocytosis can 
occur. Serum sodium, phosphorous, chloride and magnesium levels are 
reduced in ketoacidosis. There is mild elevation of blood urea nitrogen 
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and serum creatinine level. Serum levels of β hydroxybutyrate level are 
useful in diagnosis. Acetoacetate is the ketone body detected by keto 
stick. 
HYPERGLYCEMIC HYPEROSMOLAR STATE: 
It occurs as a result of decreased fluid intake and relative insulin 
deficiency. Insulin deficiency causes increased glucose output from the 
liver and decreased glucose utilization in skeletal muscle. Hyperglycemia 
causes osmotic diuresis and leads to intravascular volume loss which is 
further accentuated by decreased fluid intake. The absence of ketosis in 
hyperglycemic hyperosmolar state is not known. Studies have shown that 
the levels of counter regulator hormones and free fatty acids levels are 
low in hyperglycemic hyperosmolar state when compared to diabetic 
ketoacidosis.It is said that insulin/glucagon ratio doesn’t favors  
ketogenesis
17
. 
CLINICAL FEATURES: 
Typically patients present with weight loss, weeks history of 
polyuria and decreased oral intake which ultimately results in lethargy, 
mental confusion or coma. It is usually precipitated by sepsis, pneumonia, 
and concurrent illness such as stroke or myocardial infarction. 
Examination will reveal tachycardia, hypotension, profound dehydration, 
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hyperosmolality, and altered mental status. Absence of nausea, vomiting, 
abdominal pain and kussmaul breathing favour the diagnosis of 
hyperglycemic hyperosmolar state. 
LAB ABNORMALITIES AND DIAGNOSIS: 
Plasma glucose is usually in the range of 600-1000mg/dl. Other 
features hyperosmolality, prerenal azotemia. Potassium, magnesium, 
chloride and phosphate levels are well within normal range. Bicarbonate 
is within normal limits or slightly reduced. Secondary to starvation there 
can be mild ketonuria. 
HYPOGLYCEMIA: 
Hypoglycemia is one of the most important complications of 
diabetes. It occurs due to excess administration of insulin or oral 
hypoglycemic agent particularly in the setting of organ failure or sepsis. 
Hypoglycemia is documented by whipple′s triad.1. Reduced plasma 
blood sugar. 2. Symptoms of hypoglycemia.3.Relief of symptoms after 
giving glucose. Symptoms of hypoglycemia and blood sugar value less 
than 55mg/dl and improvement of symptoms after giving glucose 
documents hypoglycemia. 
As the blood sugar falls below the physiological range counter 
regulatory hormones comes into action. First defense is reduced insulin 
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secretion. Second defense is the glucagon, which causes hepatic 
glycogenolysis. Third is the epinephrine which stimulates hepatic 
glycogenolysis and gluconeogenesis. When hypoglycemia is for more 
than 4 hours cortisol and growth hormone comes into action and 
promotes glucose production. 
CLINICAL MANIFESTATION:  
Neuroglycopenic symptoms are due to reduced sugar level in the 
brain. Symptoms are fatigue, behavioral changes, confusion, seizures, 
loss of consciousness and if severe and prolonged it may result in death. 
Signs of hypoglycemia are pallor and diaphoresis. Blood pressure and 
heart rate are increased, but may not be increased in patients with 
recurrent episodes of hypoglycemia. 
Hypoglycemic unawareness: 
The reduced sympatho adrenal response to hypoglycemia causes 
the syndrome of hypoglycemic unawareness. It is due to loss of warning 
adrenergic and cholinergic symptoms. Affected patients are at increased 
risk of  iatrogenic hypoglycemia. 
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CHRONIC COMPLICATIONS OF DIABETES: 
It can be classified into microvascular and macrovascular. 
Microvascular complications in the eye include retinopathy and macular 
edema, diabetic nephropathy, autonomic, sensory and motor mono and 
poly neuropathy. Macrovascular complications include cerebrovascular 
disease, peripheral arterial disease and coronary artery disease. 
CORONARY ARTERY DISEASE: 
Diabetes mellitus patients have many different forms of 
dyslipidemia. Common forms are reduced high density cholesterol, 
increased triglyceride level and the small dense lipoprotein particles 
found in patients with diabetes have more atherogenic potential and they 
are more easily glycated and susceptible to oxidation
23
. Somes  of the risk 
factors for coronary artery disease in diabetic patients are cigarette 
smoking, reduced physical activity, obesity, dyslipidemia  and 
hypertension. The association between insulin resistance and 
hypertension and the subsequent hyperinsulinemia is well established. 
Patients who were not on treatment for essential hypertension, have 
elevated levels of insulin level in the fasting and postprandial state when 
compared to the normotensive people regardless of bodymass index. Thus 
these statements say that hypertension is an insulin resistance state
24
. 
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Some of the additional risk factors associated with diabetes are 
macroalbuminuria, microalbuminuria, abnormal platelet function and 
increased serum creatinine level. Patients with diabetes and insulin 
resistance have elevated levels of fibrinogen and plasminogen activator 
inhibitors. These substances augments the coagulation process and 
impairs fibrinolysis
25
. Thus leading to easy formation of thrombosis. 
Diabetic patients have impaired vascular smooth muscle and endothelial 
dysfunction, these also contributes to thrombus formation, thus increasing 
the cardiovascular morbidity and mortality .Diabetic patients have 
fourfold (in women) and two fold (in men) increase in mortality due to 
cardiovascular events
17
. 
Coronary artery disease occurs in Type1 diabetic patients usually 
in the third or fourth decade of life, regardless of the development of 
diabetes in the child hood or early adolescence. After the age of 40 years 
coronary artery disease risk increases rapidly and by 55 years 35% of 
women and men will die of coronary artery disease when compared to 
8% without diabetes. 
CEREBRO VASCULAR DISEASE: 
Type 1 and Type 2 diabetic patients are more prone for stroke. 
Diabetes increases carotid atherosclerosis and mortality due to stroke is 
 28 
about threefold high
26
. Studies have shown that using statin therapy was 
significantly associated with reduced incidence of stroke. 
DIABETIC NEUROPATHY: 
Studies have shown that the prevalence of diabetic peripheral 
neuropathy is from 5%to 100%.The most common form of diabetic 
neuropathy is predominantly sensory or sensory motor distal 
polyneuropathy. Classification is based on clinical presentation. Modified 
classification of diabetic neuropathy by Thomas is shown below
27
: 
SYMMETRIC NEUROPATHY: 
 Distal symmetric sensory motor polyneuropathy. 
 Hyperglycemic neuropathy 
 Autonomic neuropathy 
 Acute painful neuropathy 
 Treatment induced neuropathy 
 Symmetric proximal lower extremity neuropathy 
FOCAL AND MULTIFOCAL NEUROPATHY 
 Diabetic amyotrophy 
 Focal limb neuropathy 
 Cranial neuropathy 
 Thoraco abdominal neuropathy 
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Clinical Features: 
Paresthesias and numbness starts in the toes and gradually ascends 
to involve the feet and lower legs. Sensory deficit usually occurs in a 
symmetric pattern but not infrequently asymmetric pattern of nerve 
distribution may superimpose on this symmetric distribution. The distal 
portions of the longer nerves of the lower extremities are affected first 
producing the typical stocking and glove pattern. These symptoms are 
often described as like walking on pebbles, having cotton bunched up 
under the toes. The positive symptoms are superficial burning, deep 
burning, parasthesia, dysesthesia, paroxysmal jabbing pain and contact 
induced discomfort .Sensory symptoms are commonly accompanied by 
mild distal motor weakness and autonomic neuropathy. 
Involvement of myelinated large fibers and unmyelinated  small 
fibers occurs In varying  combination. Small fiber neuropathy produces 
defects in pain and temperature perception, dysesthesias, paresthesias, 
dysautonomia, defect in perception of visceral pain and predisposition to 
foot ulceration. Deep tendon reflexes and proprioception are relatively 
preserved. Nerve conduction studies are usually normal or minimally 
abnormal. Involvement of large fiber neuropathy cause loss of position 
and vibration position sense and absent deep tendon reflexes. Nerve 
conduction studies are abnormal. 
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OCULAR COMPLICATIONS OF DIABETES: 
Diabetic retinopathy is one of the most important complications of 
diabetes. Other complications include, mononeuropathies involving the 
3
rd
,4
th 
 and 6
th
 nerve, decreased sensitivity and recurrent erosion in the 
cornea, neovascularisation of  iris and neovascular glaucoma, refractive 
fluctuations, premature cataract and diabetic cataract. 
In the United States diabetes is the leading cause of blindness in 
the age group 20 and 74 years
28
. Individuals with diabetes have 25 times 
more risk of becoming blind. Causes of blindness include clinically 
significant macular edema and diabetic retinopathy. Retinopathy can be 
classified into proliferative and non proliferative retinopathy. Non 
proliferative diabetic retinopathy occurs after 10 to 20 years of diabetes. 
Non proliferative diabetic retinopathy is characterized by vascular 
microaneurysm, cotton wool spots and blot hemorrhages. More extensive 
disease is characterized by more microaneurysm formation and 
hemorrhages, intra retinal microvascular abnormalities and change in 
venous vessel caliber
29
.The pathophysiology involved in the formation of 
non proliferative diabetic retinopathy are abnormal retinal 
microvasculature, alteration in the retinal blood flow, loss of retinal 
pericytes and increased vascular permeability, all these leads to retinal 
ischemia. 
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The hall mark of proliferative diabetic retinopathy is 
neovascularization  in response to retinal hypoxia
17
.The new vessels 
usually appear near the macula or the optic nerve.The rupture of newly 
formed vessels leads to vitreous hemorrhages, fibrosis and ultimately 
leads to retinal detachment. The more severe the non proliferative 
retinopathy more the chance of getting proliferative diabetic retinopathy 
within 5 years. The best predictors for the development of the diabetic 
retinopathy are duration of diabetes and degree of glycemic 
control.Macular edema usually occurs only when there is non 
proliferative retinopathy.Fundus fluorescein angiography can detect 
macular edema and when it is present the chance of developing moderate 
visual loss in the next 3 years in 25%. 
DIABETIC NEPHROPATHY: 
Among diabetic patients only 30% develop diabetic nephropathy. 
The sibling of a diabetic patient with type 1 diabetes  without 
nephropathy has  a 25%risk of getting  diabetic nephropathy. The sibling 
of a type 1 diabetic patient with nephropathy has a 72% risk of 
developing nephropathy
30
. Thus inherited factors play an important role 
in the development of diabetic nephropathy. Familial predisposition to 
raised blood pressure is an important determinant of susceptibility to 
renal disease in patients with diabetes. The risk of nephropathy is 3 times 
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higher in type 1 diabetic patients who have history of hypertension in 
atleast one parent
31
. The prevalence of proteinuria is higher in those 
parents who are hypertensive when compared to normotensive. Studies 
have shown that mean blood pressure levels are high in patients who 
progress to microalbuminura than those who do not
32
. 
PATHOGENESIS OF DIABETIC NEPHROPATHY: 
The main mechanisms involved in the pathogenesis of diabetic 
nephropathy are, 
    1. Metabolic insults 
    2. Hemodynamic insults 
    3. Inflammatory mediators  
    4. Signalling pathways. 
METABOLIC INSULTS: 
 HYPERGLYCEMIA: 
Poor glycemic control is associated with diabetic nephropathy. 
HbA1c levels are higher in patients with micro and macro albuminuria, 
when compared to normoalbuminuria
33
.High blood sugar levels induces 
hypertrophy of mesangial cells and protein secretion of extracellular 
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matrix components such as collagen, laminin and fibronectin. 
Hyperglycemia reduces the activity of metalloproteases,which is an 
enzyme responsible for degradation of extracellular matrix. The four 
hypothesis by which hyperglycemia induces renal damage are,  
1. Formation of advanced glycated end products. 
2. Increased polyol pathway flux 
3. Activation of protein kinase 
4. Increased  hexosaminase pathway flux. 
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FORMATION OF ADVANCED GLYCATION END PRODUCTS: 
Non enzymatic glycation of proteins is a physiological reaction 
which is enhanced in the presence of hyperglycemia. The glycated 
proteins undergo progressive dehydration, cyclization, oxidation and 
rearrangement to form advanced glycation end products. Once these 
products are formed the reaction is irreversible and they gradually 
accumulate over the life time of protein
34
.AGEs accumulate in the 
glomeruli and tubules and leads to albuminuria ,mesangial expansion and 
thickening of glomerular basement membrane. Interaction of AGE- 
modified proteins with its receptors degrades AGE proteins but also 
stimulates the synthesis and release of cytokines such as platelet derived 
growth factor, transforming growth factor β and insulin like growth 
factor, these results in increased production of fibronectin, collagen and 
laminin
35,36
.Overexpression of AGE receptors  rapidly develops 
glomerular lesion similar to diabetic nephropathy.It is also expressed in 
tubular epithelial cells and upon activation  induce  tubular epithelial cell 
trans differentiation  to myofibroblast which leads to the development of 
interstitial fibrosis
37
. 
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Figure showing : Formation of advanced glycated end products 
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THE POLYOL PATHWAY: 
Intracellular glucose is predominantly metabolized by 
phosphorylation and glycolysis and when there is hyperglycemia, the 
excess glucose is converted to sorbitol by the enzyme aldose reductase, 
excess sorbitol is oxidized to fructose by the enzyme fructose 
dehydrogenase .Increased activity of polyol pathway  was demonstrated 
in diabetic patients
38
.Fructose is a reactive sugar that leads to the 
formation of advanced glycated end products. The increased ratio of 
NADH/NAD and in addition of oxidation of sorbitol to fructose results in 
the formatin of reactive oxygen species
39
. 
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Figure showing : Formation of Sorbitol  
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HEXOSAMINE  BIOSYNTHETIC  PATHWAY: 
Small amount of glucose entering into the cell is metabolized by 
the hexosamine biosynthetic pathway, which converts glucose 6 
phosphate into hexosamine 6 phosphate.The rate limiting enzyme in this 
reaction is the glutamine: fructose 6 phosphate aminotransferase. In 
patients with diabetic nephropathy there is overexpression of this enzyme. 
This leads to increased formation of transforming growth factor β and 
fibronectin
40
. 
HEMODYNAMIC INSULTS: 
  These are due to systemic hypertension and glomerular 
hypertension. Hypertension plays an important role in the development of 
diabetic nephropathy. Proteinuria correlates well with the gradual rise in 
the systemic blood pressure. There is a significant correlation between the 
blood pressure levels and rate of decline in glomerular filtration rate
41
. 
Studies have shown that patients with type1 and type 2 diabetes with 
normal albumin excretion with higher mean arterial blood pressure 
progress to microalbuminuria, when compared to those with normal mean 
arterial pressure
42
. 
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Intra glomerular pressure is regulated by the precise adjustment of 
the afferent and efferent arteriolar resistance.In diabetic patients there is 
loss of autoregulation of glomerular capillary pressure. Hyperglycemia 
causes vasodilation and in diabetic patients there is a marked reduction in 
the afferent and lesser reduction in the efferent arteriolar resistance.This 
leads to elevated glomerular pressure
43
.When there is any change in the 
systemic pressure it gets reflected in the glomerular pressure.The 
mechanism by which increased glomerular capillary pressure leads to 
kidney damage is due to the unique elastic properties of the glomerular 
structure and the response of the mesangial cells to mechanical stretch. 
 When the glomerular pressure increases, the glomerular volume 
increases by about 30%.These volume change reach their maximum in 
3to 4 seconds following alteration in the intraglomerular pressure.Thus it 
responds for a transient variation in the glomerular pressure. Mesangial 
cells are exposed to mechanical stretch in response to increase in 
glomerular pressure. Cyclical stretch stimulates the synthesis of 
deposition of matrix components such as fibronectin, laminin and 
collagen in proportion to the intensity of the stretch
44
. 
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PROTEINURIA: 
Proteinuria is an independent predictor of decline in renal function 
in diabetic Nephropathy
45
. Proteinuria leads to excessive tubular 
reabsorption of proteins and leads to accumulation of proteins in the 
tubular epithelial cells. These causes release of vasoactive and 
inflammatory cytokines such as osteopontin, monocyte chemo attractant 
protein1,and endothelin 1.These factors leads to over expression of 
proinflammatory and fibrotic cytokines and which causes injury to the  
tubulointerstitium and finally leads to renal scarring and renal failure
46
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INFLAMMATORY MEDIATORS: 
      Molecular mediators such as transforming growth factor 
1β,connective tissue growth factor, growth hormone and insulin like 
growth factor, vascular endothelial growth factor  and angiotension 2  
plays an important role in the pathogenesis of diabetic nephropathy 
TRANSCRIPTION FACTORS AND INTRCELLULAR 
SIGNALLING PATHWAYS: 
       Transcription factors such as nuclear factor-k B, fos, jun and the AP 
1transcription factors play a key role in the pathogenesis of diabetic 
nephropathy. 
In diabetes diacyl glycerol levels are increased and protein kinase 
C is activated in variety of tissue including kidneys. Protein kinase C is a 
crucial downstream mediators of angiotensin 2, transforming growth 
factor β, vascular endothelial growth factor and cyclic stretch signaling. 
Thus showing that protein kinase C activation is the key intracellular 
target in both metabolic and hemodynamic insults. Mitogen activated 
protein kinases such as extracellular signal related kinases, p38 kinases 
and stress activated protein kinases plays an important role
47
. 
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stretch 
 
protein kinase C 
 
                                             p38 kinases                              ↑ fibronectin 
mitogen activated protein kinase 
                      
↑   transforming growth factor β 
 
This is the schematic representation of stretch induced activation of 
protein kinase C and p38 kinase plays an important role in the production 
of fibronectin and transforming growth factor β. 
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Metabolic insult          Hemodynamic insult 
                                          Hypertension 
 
                                      Signaling pathways                            Proteinuria 
AGE                             ( DAG-PKC,MAPK) 
 
                                           Cytokines 
 ECM                      (TGF-β1, CTGF,VEGF,Ang 2) 
Cross linking 
                              ECM                         Vascular permeability 
           
             ECM accumulation                         Proteinuria 
This is the schematic representation of the interaction at the cellular 
and intracellular level in diabetic nephropathy. 
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NATURAL HISTORYAND CLINICAL MANIFESTATION OF 
DIABETIC NEPHROPATHY: 
It takes years to develop kidney disease in diabetic patients. In type 
1 Diabetics it takes about 5 to15 years to develop diabetic nephropathy 
.In type 2 diabetics nephropathy can be present at the time of diagnosis, 
because most patients are asymptomatic or have only mild symptoms for 
quite long time before the diagnosis is made. Therefore the screening for 
diabetic nephropathy should be done at the time of diagnosis in type 2 
diabetes and 5 years after the diagnosis in type 1 diabetes. 
The earliest manifestation of diabetic nephropathy is the presence 
of albumin in Urine
48
 .Microalbuminuria is the excretion of 30 to 299mg 
of albumin in 24 hours urine. Microalbuminuria has also been called as 
incipient nephropathy or early diabetic nephropathy. Macroalbuminuria is 
the excretion of more than 300mg of albumin in 24 hour urine.One year 
after the onset of diabetes there will be glomerular hyperperfusion and 
renal hypertrophy, which is associated with an increase in the GFR. GFR 
returns to normal during the first 5 years and the pathological changes 
include glomerular hypertrophy, thickening of glomerular basement 
membrane and mesangial volume expansion. In type 1 diabetes after 5 to 
10 years 40% will have microalbuminuria and only 50% will progress to 
macroalbuminuria. Once microalbuminuria sets in, there is steady decline 
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in glomerular filtration rate and about 50% will reach end stage renal 
disease in the next 7to 10 years
17
.When microalbuminuria develops the 
pathological changes are irreversible and the blood pressure rises. In type 
2 diabetics microalbuminuria or macroalbuminuria may be present at the 
time of diagnosis and hypertension more commonly accompanies micro 
or macroalbuminuria and microalbuminuria may be less predictive of 
diabetic nephropathy. Most of the time diabetic nephropathy correlates 
well with diabetic retinopathy. 
Onset of diabetes in years 
                                                                     Onset of diabetes in years 
         0          3           5         10            15           20           25  
                                                      Microalbuminuria       gross proteinuria 
 
  
GFR ml/min   120             150   150                          120           60       10< 
Serumcreatinine 1.0           0.8     0.8                           1.0            2.0      >5 
Mg/dl 
This picture shows the time course of development of diabetic 
nephropathy.The relationship of time from onset of diabetes, glomerular 
filtration rate and serum creatinine are shown in the figure. 
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Creatinine clearance should be estimated in all patients with 
nephropathy to accurately assess the renal function. 
STAGES OF DIABETIC NEPHROPATHY: 
1. Stage of hyperfunction and hypertrophy 
2. Silent stage – which is characterized by normal blood pressure and 
normal urine albumin excretion. Structural lesions such as 
increased thickening of glomerular basement membrane and 
mesangial expansion can be present. 
3. Stage of incipient diabetic nephropathy – characterized by 
persistent microalbuminuria and hypertension. 
4. Stage of overt diabetic nephropathy – characterized by 
proteinuria,hypertension and fall in glomerular filtration rate. 
5. Stage of end stage renal disease – characterized by uremia and very 
low glomerular filtration rate. 
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GLOMERULAR LESIONS: 
 Glomerular capillary basement membrane thickening 
 Diffuse  mesangial sclerosis 
 Nodular glomerular sclerosis - this is also known as 
intercapillary glomerular sclerosis or kimmelstiel –wilson 
disease. This is the characteristic histological finding in 
diabetic nephropathy. 
This is the microscopic picture of nodular glomerular sclerosis-
shown by arrow marks. 
 
Kimmelstiel Wilson lesion 
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MAGNESIUM: 
Magnesium is the fourth most abundant cation in the body and the 
second most abundant intracellular cation next only to potassium
1
.Normal 
adult human body contains 21 to 28 grams of magnesium which is 
approximately equal to 2000meq. 53% of total body magnesium is 
located in the bone  and 27%is located in the muscle,19% in soft tissue 
and 1% is located in the extracellular fluid
3
. Most of the intracellular 
magnesium occurs in bound form and only 0.25 to 1mmol occurs as free 
magnesium
49
.  
Serum concentration of magnesium ranges from 0.7 to 1mmol/l or 
1.7to 2.4mg/dl. The plasma concentration in healthy adults remain 
constant
50
.The average daily intake of magnesium is about 140 to 
360mg/day(25meq/day).Around 40% of dietary magnesium is absorbed 
in the small intestine particularly in the ileum. Elimination of magnesium 
occurs through the kidney and is about 100mg/day. The threshold for 
urinary excretion is the upper limit of normal range. When the serum 
magnesium level raise above the upper limit, excretion also increases to 
maintain the constant serum level. The main site for reabsorption of 
magnesium in the kidney is the thick ascending limb of loop of henle and 
in conditions of magnesium depletion, kidney has a strong capacity to 
reabsorb magnesium. Factors which impair renal reabsorption are volume 
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expansion, hypercalcemia and administration of diuretics such as 
thiazide, osmotic or loop diuretics. Magnesium acts as a cofactor in more 
than 300 enzymatic reaction involving protein and nucleic acid synthesis 
and energy metabolism. The active form of the element is the free ionized 
magnesium. 
REGULATION OF MAGNESIUM: 
 
Magnesium is absorbed from the gastrointestinal tract and excreted 
mainly by the kidneys. But a smaller amount is also excreted through the 
gastrointestinal secretion and a negligible amount through sweat and 
menstrual losses. The important sites of magnesium absorption are distal 
small intestine and colon
51
. Studies have shown that there is a direct 
correlation between magnesium absorption and dietary or luminal 
magnesium load. Absorption occurs through paracellular and transcellular 
pathway. Magnesium is re excreted into the intestine by bile ,pancreatic 
and other intestinal excretion and cell sloughing
52
.The fractional 
absorption of ingested magnesium  depends on the amount of magnesium 
in the food and the presence of enhancing or inhibiting substances in the 
food and the magnesium hemostasis
53
. 
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Renal Excretion: 
The kidney is the main organ that regulates magnesium 
homeostasis. Around 80% of the magnesium is filtered through the 
glomerulus. The important sites of magnesium reabsorption are the thick 
ascending limb of loop of henle(70-80%) ,the proximal tubule(5-
15%),and the distal convoluted tubule (5-10%). 3% of filtered 
magnesium appears in the urine
54
.The mechanism by which magnesium 
gets reabsorbed is mainly by paracellular pathway in the loop of henle 
and transcellular pathway in the proximal and distal tubules .Studies have 
shown that magnesium absorption increases in magnesium deficiency. 
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 This is the schematic representation showing the renal handling of 
magnesium. Certain hormones play an important role in magnesium 
homeostasis. Hormones which increase serum magnesium level are
55
 
 Parathyroid hormone 
 Glucagon 
 1,25 dihydroxy cholecalciferol 
Hormones which decreases serum magnesium level are, 
 Aldosterone 
 Vasopressin 
 Calcitonin 
 Thyroxine 
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FOOD SOURCES OF MAGNESIUM
61 
   (Magnesium content in mg/100gm) 
Legumes 
 Split beans- 50 
 Soyabean – 86 
Nuts 
 Peanuts -175 
 Almonds -315 
 Cashews -260 
Dairy products 
 Milk -24 
 Butter -20 
 Yoghurt -12 
Fruits 
 Dates -35 
 Banana -30 
 Oranges -10 
 Apple -5 
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Cereals 
 Shredded wheat – 110 
 Rice -40 
Meat and fish 
 Pork -22 
 Chicken -21 
 Beef - 18 
 Fish -22 
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Recommended dietary allowances of magnesium as developed by 
Food and Drug Administration
56
: 
AGE MALE FEMALE PREGNANCY LACTATION 
 
1 – 3 
 
80 
 
80 
 
NA 
 
NA 
 
4 – 8 
 
130 
 
130 
 
NA 
 
NA 
 
9 – 13 
 
240 
 
240 
 
NA 
 
NA 
 
14 -18 
 
410 
 
360 
 
400 
 
360 
 
19 - 30 
 
400 
 
310 
 
350 
 
310 
 
31+ 
 
420 
 
320 
 
360 
 
320 
Magnesium values in mg/day. 
BIOCHEMICAL IMPORTANCE OF MAGNESIUM: 
Magnesium is an activator of our enzyme system which are 
particularly involved in cellular metabolism. Important enzymes are one 
which hydrolyze and transfer phosphate groups ,especially the reaction 
involving adenosine phosphate. As adenosine tri phosphate is required for 
fat, protein , glucose utilization ,nucleic acid and coenzyme synthesis 
,muscle contraction and other reactions, by inference magnesium has an 
active role in the above reactions. 
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            Magnesium is required as a cofactor in oxidative phosphorylation, 
which occurs in the mitochondria. The highly ordered organization of 
DNA, RNA and ribosome  is stabilized by the presence of magnesium. 
Magnesium is involved in protein synthesis
58
. It helps in binding of the 
messenger RNA to the 70s ribosome. 
          The second messenger cyclic adenosine  monophosphate is 
involved in many reaction including secretion of hormones such as 
parathyroid hormone. Cyclic adenosine monophosphate is formed from 
magnesium adenosine triphosphate and the enzyme adenylate cyclase, 
which is activated by magnesium by its two binding sites
57
.Magnesium is 
also involved in membrane stabilization , ion transport and calcium 
channel activity
60
.As magnesium takes part in many cellular activities ,it 
plays an important role in control of neuronal activity, cardiac 
excitability, muscle contraction, neuromuscular transmission, vasomotor 
tone , blood pressure and peripheral blood flow
59
. 
Causes of  hypomagnesemia
62
: 
o Impaired intestinal absorption 
 Primary infantile hypomagnesemia 
 Malabsorption syndrome 
 Vitamin D deficiency 
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o Increased intestinal loss 
 Intestinal drainage, fistula 
 Protracted vomiting, diarrhea 
o Impaired renal tubular absorption 
 Genetic magnesium wasting syndrome 
 Bartter syndrome 
 Gitelman syndrome 
 Na K ATP ase  g-subunit mutation 
 Acquired renal disease 
 Tubulointerstitial disease 
 Renal transplantation 
 Post obstruction/Acute tubular necrosis ( diuretic phase) 
o Drugs 
 Ethanol 
 Diuretics(osmotic, loop and thiazide) 
 Cisplatin, Cyclosporin 
 Aminoglycosides, Amphotericin B 
o Metabolic causes 
 Diabetes mellitus 
 Metabolic acidosis 
 Hyperaldosteronisim 
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 Syndrome of inappropriate ADH secretion 
 Hypercalcemia 
 Hyperthyroidism 
o Others 
 Pancreatitis 
 Excessive sweating 
 Osteoblastic metastasis 
Clinical  features of  hypomagnesemia 
Patient may present with non specific symptoms. Symptoms 
include weakness, muscle cramps, vertigo, ataxia, depression, seizure and 
altered mental status. Symptoms and signs occur only when serum 
magnesium concentration  is less than 1.2mg/dl. 
SIGNS
63
: 
 Muscle cramps 
 Hyperactive deep tendon reflexes 
 Trousseau and chovstek sign 
 Dysphagia due to esophageal dysmotility 
 Irritability /disorientation 
 Ataxia, nystagmus and seizure 
 Tachycardia 
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ECG changes: 
ECG changes in hypomagnesemia are non specific. Modest level of 
magnesium deficiency causes widening of the QRS complex and peaking 
of T wave. Severe magnesium deficiency causes prolongation of PR 
interval, progressive widening of QRS complex, flattening/inversion of T 
wave and U wave
64
. 
MAGNESIUM AND DIABETES: 
Magnesium plays an important role in carbohydrate metabolism. 
Diabetes mellitus is one of the most common metabolic disorder 
associated  with magnesium deficiency. The prevalence of magnesium 
deficiency in diabetes is around 25-39%
65
. 
Aetiology of  hypomagnesemia in diabetes
66,67
: 
 Diet tends to be low in magnesium 
 Reduced intestinal absorption of magnesium 
 Inceased renal magnesium loss due to glycosuria 
 Insulin effect causes redistribution of  magnesium from plasma 
to red blood cells. 
 Insulin insensitivity affects  magnesium transport and glucose 
metabolism 
 Loop and thiazide diuretic use promotes  magnesium loss. 
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 A specific tubular defect has been postulated for magnesium 
deficiency in diabetes. The site of the defect is not yet defined. The 
proposed site of defect is the thick ascending limb of loop of henle or 
more distally. Reduced tubular magnesium absorption results in 
hypermagnesuria. Treatment with insulin will correct renal magnesium 
loss. 
Role of Magnesium in Glucose homeostasis and insulin sensitivity: 
In patients with diabetes magnesium deficiency have shown a 
negative impact on glucose homeostasis and insulin sensitivity
68
. In 
diabetics uptake of magnesium in erythrocytes in response to insulin is 
reduced. This change was associated with an increase in erythrocyte 
membrane microviscosity
69
.Changes in the physical state of plasma 
membrane and insulin resistance were responsible for the lower 
erythrocyte magnesium level .Plasma membrane changes impair the 
interaction of insulin with its receptors and reduces glucose tolerance. 
The reduced insulin sensitivity is due to defective tyrosine kinase activity 
of the insulin receptor. Several enzymes are involved in glucose 
metabolism , which requires high energy phosphate bonds. Magnesium 
acts as a cofactor in these enzymatic reactions. Intracellular magnesium 
deficiency leads to worsening of insulin action and insulin resistance. 
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Thus low magnesium level contributes to insulin resistance ,which in turn 
reduces magnesium uptake in insulin sensitive tissues. 
Magnesium and diabetic nephropathy: 
Diabetic nephropathy is one of the most important micro vascular 
complication of diabetes. Na/K- ATPase plays an important role in the 
development of diabetic nephropathy. Na/K-ATP ase is involved in the 
maintenance  of  gradients of Na and K and in glucose transport. 
Magnesium acts as a cofactor in these reactions. Magnesium deficiency 
affects the activity of Na/K-ATPase. Studies have shown that the affinity 
of  inositol transporter  was increased by magnesium. Magnesium 
deficiency augments intracellular inositol depletion
70
, which results in 
reduced activity of regulatory proteins and leads to diabetic nephropathy. 
Further more in worsening diabetic nephropathy, there is increase in 
vasoconstrictor prostaglandins and thromboxane A2 
71
, which leads to 
increase in filtration pressure and damage to the basal membrane which 
causes reduction in glomerular filtration rate and proteinuria. Elevated 
lipid levels and increase in Thromboxane A2   synthesis  plays an 
important role in progression of diabetic nephropathy
72
. 
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Magnesium deficiency and other complications of diabetes: 
Magnesium deficiency has also been implicated in some of the 
other complications of diabetes. Studies have shown that low serum 
magnesium was associated with severe background and proliferative 
diabetic retinopathy. Diabetic neuropathy and peripheral vascular disease 
contributes to the development of foot ulcers. Studies have shown that 
there is a strong association between low serum magnesium level and 
development of foot ulcers in diabetes
73
. 
Magnesium and Dyslipidemia: 
Magnesium plays an important role in lipid metabolism. 
Dyslipidemia is strongly associated with magnesium deficiency. 
Magnesium modulates HMG-CoA reductase which is the rate limiting 
enzyme involved in cholesterol metabolism. Deficiency of magnesium is 
associated with decrease in HDL, inhibition of the enzyme lipoprotein 
lipase and elevation of triglyceride level. 
Osteoporosis and Magnesium: 
Deficiency of magnesium increases the risk of osteoporosis. 
Diabetics have reduced bone mass which is due to decreased 
parathormone. In diabetics reduced serum magnesium level and increase 
in serum ionized calcium level inhibits parathormone secretion
74
. 
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Hypertension and Magnesium: 
Magnesium is an activator of  Na K- ATPase and it also acts as a 
calcium antagonist
75
.Deficiency of magnesium causes increase in 
intracellular concentration of calcium and potassium which causes 
vasoconstriction and increase in peripheral vascular resistance. Studies 
have shown that there is an inverse correlation between blood pressure 
and serum magnesium level. 
Magnesium and coronary artery disease: 
Magnesium deficiency is a risk factor for coronary artery disease. 
Studies have shown that magnesium supplementation may have added 
antithrombotic effect with aspirin and improve exercise tolerance. 
Magnesium and acute myocardial infarction: 
Reduced magnesium is often found in acute myocardial infarction. 
In acute myocardial infarction , when there is mild hypomagnesemia  the 
risk of ventricular arrhythmia in the first 24 hours is high. Studies have 
also shown that ventricular arrhythmias occurring in the second or third 
week after acute myocardial infarction is associated with low serum 
magnesium level
77
. 
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Oral supplementation of magnesium: 
Studies have shown that magnesium supplementation have shown 
to improve insulin secretion and increased insulin sensitivity
78
. Studies 
have also shown that magnesium supplementation  may reduce platelet 
aggregation  probably by decreasing Thromboxane A2   level
79
.Studies 
have also shown that magnesium supplementation has reduced low 
density lipoprotein and cholesterol
80
. Few studies have also shown that 
moderate decrease in systolic blood pressure after supplementation of 
magnesium
81
.As magnesium deficiency has been implicated as an 
important reason in the development of complication of diabetes, 
supplementing  oral magnesium can improve glycemic control and can 
prevent the complication of diabetes.   
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AIM OF THE STUDY  
To study the correlation of serum magnesium in diabetic 
patients with proteinuria. 
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MATERIALS AND METHODS 
This is an observational study, done at Government Royapettah 
Hospital in the department of Medicine. The study protocol was approved 
by the Ethical committee for research studies of Government Kilpauk 
Medical College and Hospital, Chennai. 
The study period was between July 2012 – December 2012.The 
patients recruited in the study were patients admitted in the general 
medical ward for control of diabetes and patients attending diabetology 
department as outpatients in Government Royapettah Hospital. 
INCLUSION CRITERIA 
• Patients with Type 2 Diabetes 
• Type 1 Diabetes > 5yrs duration 
EXCLUSION CRITERIA 
• Systemic Hypertention 
• Congestive cardiac failure 
• Urinary tract infection 
• Severe diarrhea 
• Alcoholics 
• Ketoacidosis 
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• Total parentral  nutrition 
• Drugs causing hypomagnesemia 
 
 Detailed clinical profile of each patient was noted and 24hrs urine 
protein was estimated, 2 – 5ml of blood was drawn from the patient. 
Blood was allowed to clot and serum was separated by centrifugation and 
serum magnesium was estimated by calorimetric method. Similarly blood 
was drawn to estimate blood sugar, lipid profile, HbA1c and serum 
creatinine. 
 
 Statistical analysis was done to identify the significance of 
correlation between serum magnesium and proteinuria. Statistical 
analysis was done using Statistics Products Services Solution (SPSS) 
15.Other variables used in the study were also correlated with serum 
magnesium. 
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OBSERVATIONS AND RESULTS 
Total numbers of patients included in the study were 50.Out of 
which 12 patients were type 1 diabetics and 38 were type 2 diabetics. 
 
In type 1 diabetics 3 patients had macroalbuminuria and 9 patients 
had microalbuminuria. 
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In type 2 diabetics out of 38 patients 22 had macroalbuminuria and 
16 had microalbuminuria. 
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VARIABLES ANALYSED 
 N Range Minimum Maximum Mean Std. Deviation 
DURATION OF DIABETES 50 15 7 22 13.20 4.271 
FASTING BLOOD SUGAR 50 164 125 289 184.74 34.723 
POST PRANDIAL SUGAR 50 168 174 342 250.68 43.679 
HbA1c 50 3.0 6.8 9.8 7.704 .7500 
HDL 50 31 28 59 43.08 9.147 
LDL 50 202 74 276 153.68 51.963 
TOTAL CHOLESTEROL 50 56 200 256 222.78 14.063 
TRIGLYCERIDE 50 169 116 285 216.08 34.457 
SERUM CREATININE 50 1.2 .7 1.9 1.150 .2697 
SERUM MAGNESIUM 50 .4 1.4 1.8 1.592 .1209 
age 50 55 24 79 52.80 14.988 
Valid N (listwise) 
24 hours urinary protein 
 
50 
50  56 1698 467.26 368.166 
 
The mean duration of diabetes in the study is 13.20 and mean 
serum magnesium concentration is around is 1.592. 
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Duration of diabetes and serum magnesium – correlation, Fasting 
blood sugar and serum magnesium- correlation. 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 DURATION OF DIABETES 13.20 50 4.271 .604 
SERUM MAGNESIUM 1.592 50 .1209 .0171 
Pair 2 FASTING BLOOD SUGAR 184.74 50 34.723 4.911 
SERUM MAGNESIUM 1.592 50 .1209 .0171 
 
Paired Samples Correlations 
 N Correlation Sig. 
Pair 1 DURATION OF DIABETES & 
SERUM MAGNESIUM 
50 -.882 .000 
Pair 2 FASTING BLOOD SUGAR & 
SERUM MAGNESIUM 
50 -.720 .000 
 
From the above observation it is clear that there is an inverse 
correlation between the duration of diabetes and serum magnesium and 
fasting blood sugar and serum magnesium level. 
        The chart below shows the correlation of serum magnesium levels 
and duration of diabetes. As the duration of diabetes increases serum 
magnesium level reduces.  
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The   above chart shows the correlation of serum magnesium level 
with fasting blood sugar. Poor glycemic control reduces serum 
magnesium level. 
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HDL and serum magnesium – correlation. LDL  and  serum 
magnesium correlation. 
Paired Samples Statistics 
 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 HDL 43.08 50 9.147 1.294 
SERUM MAGNESIUM 1.592 50 .1209 .0171 
Pair 2 LDL 153.68 50 51.963 7.349 
SERUM MAGNESIUM 1.592 50 .1209 .0171 
 
Paired Samples Correlations 
 N Correlation Sig. 
Pair 1 HDL & SERUM MAGNESIUM 50 .820 .000 
Pair 2 LDL & SERUM MAGNESIUM 50 -.866 .000 
 
Above table shows there is a positive correlation between serum 
magnesium level and HDL cholesterol and a negative correlation between 
serum magnesium level and LDL cholesterol. 
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The graph below shows that, when the LDL levels are high the 
serum magnesium  levels are low and higher the HDL values higher the 
serum magnesium levels. 
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Total cholesterol and serum magnesium – correlation, Triglyceride 
and serum magnesium- correlation, 24hrs urinary protein and serum 
magnesium- correlation, Low density lipoprotein and serum magnesium- 
correlation 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 TOTAL CHOLESTEROL 222.78 50 14.063 1.989 
SERUM MAGNESIUM 1.592 50 .1209 .0171 
Pair 2 TRIGLYCERIDE 216.08 50 34.457 4.873 
SERUM MAGNESIUM 1.592 50 .1209 .0171 
Pair 3 24 HRS URINARY PROTEIN 472.18 50 381.233 53.914 
SERUM MAGNESIUM 1.592 50 .1209 .0171 
Pair 4 LDL 153.68 50 51.963 7.349 
SERUM MAGNESIUM 1.592 50 .1209 .0171 
 
Paired Samples Correlations 
 N Correlation Sig. 
Pair 1 TOTAL CHOLESTEROL & 
SERUM MAGNESIUM 
50 -.621 .000 
Pair 2 TRIGLYCERIDE & SERUM 
MAGNESIUM 
50 -.847 .000 
Pair 3 24 HRS URINARY PROTEIN & 
SERUM MAGNESIUM 
50 -.869 .000 
Pair 4 LDL & SERUM MAGNESIUM 50 -.866 .000 
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From the above observation it is clear that there is an inverse 
correlation between serum magnesium levels and cholesterol, 
triglyceride, 24hrs urinary protein and LDL levels. 
 
The above graph shows that, when the serum cholesterol, 
triglyceride and LDL levels are high the serum magnesium levels are low.  
               The graph below shows that, the serum magnesium levels are 
low when there is increase in proteinuria, similarly higher the serum 
cholesterol, triglyceride and LDL lesser the serum magnesium level. 
 
 
 77 
 
HbA1c and serum magnesium- correlation: 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 HbA1c 7.704 50 .7500 .1061 
SERUM MAGNESIUM 1.592 50 .1209 .0171 
 
Paired Samples Correlations 
 N Correlation Sig. 
Pair 1 HbA1c & SERUM 
MAGNESIUM 
50 -.861 .000 
 
The above table shows that there is an inverse correlation between 
serum magnesium level and HbA1c level. 
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  The graph below shows that, as the HbA1c levels are on the higher 
side the serum magnesium are on the lower side. 
 
Serum magnesium and serum creatinine- correlation: 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 SERUM CREATININE 1.150 50 .2697 .0381 
SERUM MAGNESIUM 1.592 50 .1209 .0171 
 
Paired Samples Test 
 df Sig. (2-tailed) 
    
Pair 1 SERUM CREATININE - 
SERUM MAGNESIUM 
49 .000 
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From the above observation it is clear that there is an inverse 
correlation between serum magnesium and serum creatinine. 
 
The above graph shows as the serum creatinine increases serum 
magnesium decreases. 
Serum magnesium and 24 hrs urinary protein – correlation 
Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean 
Pair 1 24 HRS URINARY PROTEIN 472.18 50 381.233 53.914 
SERUM MAGNESIUM 1.592 50 .1209 .0171 
 
Paired Samples Correlations 
 N Correlation Sig. 
Pair 1 24 HRS URINARY PROTEIN & 
SERUM MAGNESIUM 
50 -.869 .000 
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From the above table it is clear that , there is an inverse correlation 
between serum magnesium level and 24 hours urinary protein. 
        The graph below shows that, higher the proteinuria ,lesser the serum 
magnesium level. 
 
Duration of diabetes and serum magnesium – correlation: 
Correlations 
 
DURATION OF 
DIABETES 
24 HRS URINARY 
PROTEIN 
DURATION OF DIABETES  .000 .836
** 
50 50  
.836** 1  
24 HRS URINARY PROTEIN .000   
50 50  
N   
**. Correlation is significant at the 0.01 level (2-tailed). 
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From the above observation it is clear that, there is a positive 
correlation between serum magnesium and 24 hrs urinary protein. 
The graph below shows as the duration of diabetes increases, 
proteinuria increases. The mean duration of diabetes above which 
macroalbuminuria occurs is around 13years. 
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DISCUSSION 
Our study enrolled 50 patients, out of which 12 were type 1 
diabetics and 38 were type 2 diabetics. The mean duration of diabetes in 
our study is 13 years and mean serum magnesium level is 1.592 and mean 
proteinuria is 467.26 
The important finding in our study was there is an inverse 
correlation between serum magnesium level and duration of diabetes 
.Similar finding was present in the study conducted by Nasri et al. 
Serum levels of magnesium have been found by several 
investigators to correlate inversely with fasting blood sugar and HbA1c 
levels. Schlineger et al studied the significance of glycemic control on 
various trace elements and reported significantly reduced magnesium 
level in patients with poor control of diabetes. Our study shows a 
significant inverse correlation of serum magnesium and fasting blood 
sugar and HbA1c levels. 
Hypomagnesemia is reported to be both the cause and result of 
poor glycemic control. Magnesium acts as a cofactor in both glucose 
transporting mechanism of cell membrane and enzymes involved in 
carbohydrate metabolism. Magnesium deficiency has been shown to 
promote insulin resistance in several studies. Several studies have shown 
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that daily oral magnesium supplementation improved insulin sensitivity 
by 10% and reduces blood sugar by 37%. 
Several studies have shown that there is an inverse correlation of 
serum magnesium and cholesterol, triglyceride and low density 
lipoprotein. The present study also showed there is an inverse correlation 
between serum magnesium and cholesterol, triglyceride and low density 
lipoprotein level. The present study showed a positive correlation 
between serum magnesium and high density lipoprotein level. 
Corsonello et al demonstrated significant low serum magnesium 
level in diabetic patients with micro or macroalbuminuria. Studies have 
also shown that there is a rapid decline in renal function which is 
associated with lower serum magnesium. It also shows that worse 
proteinuria was observed among patients belonging to lowest magnesium 
groups. The present study also shows there is an inverse correlation 
between serum magnesium level and serum creatinine. It also shows 
more proteinuria in patients with low serum magnesium and worsening 
serum creatinine. The present study also shows, proteinuria increases as 
the duration of diabetes increases and serum magnesium level decreases 
as the duration of diabetes increases. 
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Hyperglycemia enhances non enzymatic glycation of proteins. 
Glycated proteins transform into advanced glycated end products. These 
advanced glycated end products gets accumulated in the glomerulus and 
tubules and these products causes mesangial expansion, thickening of 
glomerular basement membrane and proteinuria.  Proteinuria is an 
independent predictor of rapid decline in renal function. Proteinuria leads 
to excessive deposition of protein in tubuloepithelial cells, which causes 
release of inflammatory cytokines and finally leads to renal scarring and 
renal failure. Poor glycemic control and altered lipid metabolism are 
associated with increase in urine albumin excretion rate. 
Several studies have shown that supplementing oral magnesium in 
diabetic patients can improve glycemic control, beneficial effect on lipid 
profile ,proteinuria and improvement in renal function. Diabetic 
nephropathy is one of the most common cause for end stage renal disease. 
Most common cause of death in diabetic nephropathy is cardiovascular 
event. By supplementing oral magnesium in diabetic patients can prevent 
diabetic nephropathy and reduce morbidity and mortality due to diabetes 
and its complications. 
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LIMITATIONS OF THE STUDY 
 The sample size which we took in our study is only 50.Further 
studies need to be conducted in large population to study the 
correlation. 
 Estimated glomerular filtration rate is usually used to assess renal 
function,but in our study we took only serum creatinine 
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CONCLUSION 
 Our study has shown a negative correlation between serum 
magnesium level and proteinuria. 
 There was a significant inverse correlation between serum 
magnesium and duration of diabetes. 
 High Density Lipoprotein shows a positive correlation with serum 
magnesium. 
 Serum cholesterol, triglyceride and Low Density Lipoprotein show 
a negative correlation with serum magnesium. 
 Serum magnesium levels are low in patients with high fasting 
blood sugar and high HbA1C  levels. 
 Serum creatinine showed a negative correlation with serum 
magnesium. 
 As the duration of diabetes increases, proteinuria also increases. 
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FUTURE TRENDS: 
 As the deficiency of magnesium has been implicated in a number 
of important complications of diabetes, the study implies that the 
serum magnesium level should be checked in every patients with 
diabetes. 
 Supplementing oral magnesium in diabetic patients, improves 
glycemic control and can prevent complications related to diabetes. 
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ABBREVATIONS 
 
IDF  - International  Diabetes  Federation 
CURES - Chennai Urban Epidemiology Study 
DM  - Diabetes Mellitus 
ATP  - Adenosine Tri Phosphate 
DAG  - Di Acyl Glycerol 
PKC  - Protein Kinase C 
VEGF - Vascular Endothelial Growth Factors 
ET  - Endothelin  
ROS  - Reactive Oxygen Species 
AGE  - Advanced Glycation End  Products 
TGF β - Transforming Growth Factor β 
CTGF - Connective Tissue  Growth Factor 
ECM  - Extra Cellular Matrix 
GFR  - Glomerular Filtration Rate 
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PROFORMA 
NAME:  
AGE: 
SEX: 
OCCUPATION:                                      
 
 
ADDRESS: 
 
HISTORY: 
 DURATION OF DIABETES,SYMPTOMS RELATED TO CARDIAC 
FAILURE,SYMPTOMS RELATED TO URINARY TRACT INFECTION. 
 
PAST HISTORY: 
 DIABETES MELLITUS , SYSTEMIC HYPERTENSION, CHRONIC 
DIARRHOEA,SEIZURES 
 
PERSONAL HISTORY: 
             ALCOHOL- DURATION, AMOUNT,FREQUENCY. 
 
    DRUG HISTORY 
• MAGNESIUM  SUPPLEMENTATION 
• ANTI DIABETIC , ANTI HYPERTENSIVE MEDICATIONS , CARDIAC 
DRUGS (DIURETICS) 
• DRUGS AFFECTING SERUM MAGNESIUM LEVELS 
 
 
 100 
  O/E: 
   GENERAL EXAMINATION  
 VITAL SIGNS - PULSE RATE, BLOOD PRESSURE, 
RESPIRATORY RATE 
 SYSTEMIC EXAMINATION -  CVS , RS , ABDOMEN , CNS 
 
INVESTIGATIONS 
• BLOOD SUGAR – FBS, PPBS 
• LIPID PROFILE 
• RENAL FUNCTION TESTS 
• URINE EXAMINATION for 24 hrs urinary protein. 
• SERUM MAGNESIUM 
• HbA1c  
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Sl. 
No. 
name age sex 
TYPE 
OF 
DIABE
TES 
DURATI
ON OF 
DIABET
ES 
FASTING 
BLOOD 
SUGAR 
POST 
PRAND
IAL 
SUGAR 
HbA
1c 
HD
L 
LDL 
TOTAL 
CHOLEST
EROL 
TRIGLYC
ERIDE 
24 HRS 
URINARY 
PROTEIN 
SERUM 
CREATI
NINE 
SERUM 
MAGNESI
UM 
1 muthkumar 56 male type 2 18 224 338 8.3 32 196 220 221 600mg 1.2 1.4 
2 palanivel 62 male type 2 16 168 267 8.1 35 180 253 218 545mg 1.3 1.5 
3 raj kumar 66 male type 2 13 212 287 7.9 36 193 239 215 352mg 1.3 1.6 
4 maariappan 65 male type 2 15 187 292 8.1 33 178 223 246 380mg 1.1 1.6 
5 kadar basha 59 male type 2 14 193 256 7.8 32 185 236 239 322mg 1.2 1.6 
6 mohammed 
ismail 71 male type 2 19 231 298 8.4 33 194 234 251 850mg 1.4 1.4 
7 kuppan 69 male type 2 17 234 286 8 34 187 222 241 720mg 1.3 1.5 
8 rajadurai 56 male type 2 12 153 223 7.6 56 156 211 210 250mg 1.1 1.6 
9 selvam 49 male type 2 9 147 210 7.3 52 143 213 204 212mg 1 1.7 
10 yasar rahim 79 male type 2 22 213 276 8.2 37 212 240 254 1200mg 1.5 1.4 
11 muthumari 65 male type 2 19 289 312 8.3 39 210 232 266 948mg 1.3 1.4 
12 bharathiar 49 male type 2 8 154 195 7.2 57 112 212 189 134mg 0.9 1.7 
13 aacharia 63 male type 2 15 199 238 7.9 40 183 233 243 435mg 1.1 1.6 
14 nagendran 54 male type 2 10 210 256 7.5 46 149 215 208 298mg 1.2 1.6 
15 selvaraj 64 male type 2 14 196 234 7.5 36 165 204 230 521mg 1.1 1.6 
16 abdullah 49 male type 2 7 184 209 7 54 110 202 190 140mg 1.3 1.7 
17 majeeth 48 male type 2 13 211 245 7.6 36 154 231 241 530mg 1.1 1.6 
18 narayanan 52 male type 2 8 153 231 7.1 48 145 222 189 278mg 1 1.7 
19 kalaiarasi 57 female type 2 9 146 189 7 56 119 218 190 257mg 0.9 1.6 
20 grace 50 female type 2 11 178 256 7.4 42 156 213 212 346mg 0.9 1.6 
21 vasanthi 48 female type 2 7 198 247 7 54 111 217 178 256mg 1.4 1.7 
22 lalitha bai 69 female type 2 16 213 265 7.4 36 187 232 235 736mg 1.3 1.5 
23 kamala 70 female type 2 21 234 297 9.2 31 256 212 243 1100mg 1.4 1.4 
24 mahaboobe
e 71 female type 2 19 199 301 9.1 30 265 234 265 1328mg 1.2 1.4 
25 latha 40 female type 2 8 125 204 7.3 51 121 233 201 287mg 1.1 1.6 
26 prema 55 female type 2 12 189 238 7.5 42 145 224 232 265mg 1.8 1.6 
27 mary 62 female type 2 15 192 287 7.6 39 165 218 241 768mg 1.6 1.5 
28 kamala 60 female type 2 18 201 318 9 33 198 237 253 867mg 1.5 1.4 
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29 varalakshm
i 66 Female type 2 9 183 245 7.2 54 118 218 195 298mg 1.1 1.7 
30 mariamma 76 Female type 2 17 222 312 9.4 31 243 245 272 1467mg 1.7 1.4 
31 sumathi 56 Female type 2 10 134 298 8.2 39 210 231 214 345mg 1.3 1.6 
32 biju bee 49 Female type 2 8 156 212 6.9 56 98 204 168 189mg 0.9 1.8 
33 saroja 48 Female type 2 7 137 196 7 58 96 219 156 104mg 0.8 1.8 
34 anjalai 55 Female type 2 11 201 287 7.6 42 132 233 218 289mg 1.1 1.6 
35 kurshid bee 79 Female type 2 22 231 313 9.8 28 276 256 285 1698mg 1.9 1.4 
36 rahmat 
nisha 71 Female type 2 20 215 342 9.5 29 249 243 268 946mg 1.3 1.4 
37 shanti 54 Female type 2 9 189 232 7.2 52 125 215 178 169mg 1 1.7 
38 noor nisha 50 Female type 2 8 134 203 7.1 48 83 203 208 220mg 0.9 1.7 
39 kalaiselvi 26 Female type 1 11 129 189 6.9 53 78 219 187 134mg 0.9 1.7 
40 srinivasan2
8 28 Male type 1 9 143 174 6.8 59 74 212 178 86mg 0.7 1.8 
41 kudubasha 32 Male type 1 12 126 217 7 51 92 206 147 56mg 0.9 1.7 
42 muthulaksh
mi 35 Female type 1 15 168 247 7.2 43 134 243 205 540mg 1.1 1.6 
43 selvaraj 29 Male type 1 10 156 187 7.4 52 87 212 186 136mg 0.8 1.7 
44 bharathi 29 Female type 1 13 198 206 7.5 48 98 215 208 267mg 1 1.6 
45 sumathi 38 Female type 1 17 205 287 7.9 40 132 243 256 468mg 1.2 1.6 
46 vijaya 41 Female type 1 16 189 245 7.8 39 146 202 234 398mg 0.9 1.6 
47 palani 24 Male type 1 10 167 199 6.9 49 88 200 116 87mg 0.8 1.8 
48 nandagopal 30 Male type 1 14 198 245 7.1 51 102 214 198 254mg 0.9 1.6 
49 dhanalaksh
mi 27 Female type 1 12 145 210 6.8 43 120 213 210 287mg 0.7 1.7 
50 mala 39 Female type 1 15 178 233 7.7 39 128 213 212 246mg 1.1 1.6 
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